About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
Menu
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
Imprint
Privacy Statement
Disclaimer
Imprint
Privacy Statement
Disclaimer
News & Events
News
Our latest Press Releases
Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
August 5, 2024
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
June 27, 2024
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
June 20, 2024
More News
EVENTS
Meet Tubulis live
Poster
Ovarian Cancer Research Symposium, Seattle
September 20-21, 2024
Presentation
Festival of Biologics, Basel
October 15-17, 2024
Presentation
ENA 2024, Barcelona
October 23-35, 2024
Participation
TPD & Induced Proximity Summit, Boston
October 28–31, 2024
Participation
Jefferies London Healthcare Conference
November 19-21, 2024
More Events